|
1
|
Shah MA and Ajani JA: Gastric cancer-an
enigmatic and heterogeneous disease. JAMA. 303:1753–1754. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Uchiyama C, Tamura S, Nakatsuka S, Takeno
A, Miki H, Kanemura T, Nakahira S, Suzuki R, Nakata K, Takeda Y and
Kato T: Immunohistochemical consistency between primary tumors and
lymph node metastases of gastric neuroendocrine carcinoma. World J
Surg Oncol. 10:1152012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fukui H, Takada M, Chiba T, Kashiwagi R,
Sakane M, Tabata F, Kuroda Y, Ueda Y, Kawamata H, Imura J and
Fujimori T: Concurrent occurrence of gastric adenocarcinoma and
duodenal neuroendocrine cell carcinoma: A composite tumour or
collision tumours? Gut. 48:853–856. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kim BS, Park YS, Yook JH and Kim BS:
Comparison of the prognostic values of the 2010 WHO classification,
AJCC 7th edition and ENETS classification of gastric neuroendocrine
tumors. Medicine (Baltimore). 95:e39772016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Okamoto T, Ogasahara K, Fujiki M, Takagi
H, Ikeda H, Makino T, Moriga T, Kawamoto K, Sano K, Yoshida Y, et
al: Primary coexistent neuroendocrine carcinoma, hepatoid
adenocarcinoma, and tubular adenocarcinoma of the stomach with
focal trophoblastic differentiation in metastatic lymph nodes. J
Gastroenterol. 38:608–610. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yasuda K, Fujiwara H, Nomura H, Sogo Y,
Sakai K and Teramura K: A case of neuroendocrine cell carcinoma and
poorly differentiated adenocarcinoma of the stomach in synchronous
multiple cancer. Jpn J Gastroenterol Surg. 39:446–451. 2006.
View Article : Google Scholar
|
|
7
|
Park BS, Jo TY, Seo HI, Kim HS, Kim DH,
Jeon TY, Kim DH, Sim MS and Kim JY: Gastric collision tumor
(adenocarcinoma and neuroendocrine carcinoma) diagnosed as a
advanced gastric cancer. J Korean Surg Soc. 73:173–177. 2007.
|
|
8
|
Kim A, Kim SW, Song SK and Bae YK: Gastric
adenocarcinoma with coexistent hepatoid adenocarcinoma and
neuroendocrine carcinoma: A case report. Korean J Pathol. 43:79–82.
2009. View Article : Google Scholar
|
|
9
|
Jung JH, Kim YC, Kim JH, Chung HS, Cheung
DY, Kim JI, Park SH and Kim JK: A case of a gastric composite tumor
with an adenocarcinoma and a large cell neuroendocrine carcinoma.
Korean J Gastrointest Endosc. 39:93–96. 2009.
|
|
10
|
Mrόz A, Kiedrowski M, Malinowska M and
Sopyło R: Collision tumour of the stomach-adenocarcinoma and
neuroendocrine carcinoma: Case report and review of the literature.
Pol J Pathol. 2:94–97. 2009.
|
|
11
|
Jang KY, Moon WS, Lee H, Kim CY and Park
HS: Gastric collision tumor of large cell neuroendocrine carcinoma
and adenocarcinoma-a case report. Pathol Res Pract. 206:387–390.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cho KH, Chang YW, Sohn SD, Hwangbo Y, Shim
J, Jang JY, Kim HJ and Kim BH: Metastatic large cell neuroendocrine
carcinoma combined with gastric adenocarcinoma. Korean J
Gastrointest Endosc. 41:94–97. 2010.
|
|
13
|
Terada T and Maruo H: Simultaneous large
cell neuroendocrine carcinoma and adenocarcinoma of the stomach.
World J Gastroenterol. 17:4831–4834. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Miguchi M, Iseki M and Shimatani K:
Advanced gastric neuroendocrine carcinoma with an adenocarcinoma
component. Case Rep Gastroenterol. 6:52–57. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nakayama Y, Higure A, Shibao K, Sato N,
Matayoshi N and Yamaguchi K: Synchronous occurrence of early
neuroendocrine carcinoma and tubular adenocarcinoma in the stomach.
Clin J Gastroenterol. 5:307–311. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lee JH, Kim HW, Kang DH, Choi CW, Park SB
and Kim SH: A gastric composite tumor with an adenocarcinoma and a
neuroendocrine carcinoma: A case report. Clin Endosc. 46:280–283.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li S, Cao X, Jiang C and Wang Q: Combined
neuroendocrine carcinoma and adenocarcinoma in the stomach: A case
report. Oncol Lett. 7:953–955. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lipi L, Sachdev R, Gautam D, Singh J and
Mohapatra I: Triple composite tumor of stomach: A rare combination
of alpha fetoprotein positive hepatoid adenocarcinoma, tubular
adenocarcinoma and large cell neuroendocrine carcinoma. Indian J
Pathol Microbiol. 57:98–100. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang W, Xiao W, Ma H, Sun M, Chen H and
Zheng S: Neuroendocrine liver metastasis in gastric mixed
adenoneuroendocrine carcinoma with trilineage cell differentiation:
A case report. Int J Clin Exp Pathol. 7:6333–6338. 2014.PubMed/NCBI
|
|
20
|
Payet E, Pilco PI, Montes J,
Cordero-Morales A, Savitzky MJ and Stenning-Persivale K: Collision
tumour of large-cell neuroendocrine carcinoma and adenocarcinoma in
the stomach: A case report. Ecancermedicalscience. 10:6162016.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Aoyagi K, Kizaki J, Isobe T and Akaqi Y: A
case of gastric cancer with neuroendocrine carcinoma, signet ring
cell carcinoma components, and intramural metastases. Am J Case
Rep. 17:274–279. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mitchell MS, Walinchus-Foster L, Thomas L,
Shi Q, Nagori M, Khan W, Mirza W, Cortes M, Masalmeh OA, Zerti H
and Mohamed A: Synchronous adenocarcinoma and neuroendocrine tumors
of the stomach. Am J Cancer Case Rep. 4:125–128. 2016.
|
|
23
|
Mainali N, Nepal N, Kumar CP, Sinha A,
Rajbanshi S, Rauniyar S and Yadav A: Co-existence of gastric
adenocarcinoma and neuroendocrine carcinoma: A rare entity. J
Pathol Nepal. 7:1221–1223. 2017. View Article : Google Scholar
|
|
24
|
Nishikura K, Watanabe H, Iwafuchi M,
Fujiwara T, Kojima K and Ajioka Y: Carcinogenesis of gastric
endocrine cell carcinoma: Analysis of histopathology and p53 gene
alteration. Gastric Cancer. 6:203–209. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kim JJ, Kim JY, Hur H, Cho YK and Han SU:
Clinicopathologic significance of gastric adenocarcinoma with
neuroendocrine features. J Gastric Cancer. 11:195–199. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang T, Su D, Mao Z, Guo X, Wang L and
Bai L: Prognostic role of neuroendocrine cell differentiation in
human gastric carcinoma. Int J Clin Exp Med. 8:7837–7842.
2015.PubMed/NCBI
|
|
27
|
Bakkelund K, Fossmark R, Nordrum I and
Waldum H: Signet ring cells in gastric carcinomas are derived from
neuroendocrine cells. J Histochem Cytochem. 54:615–621. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yamazaki K: A gastric carcinosarcoma with
neuroendocrine cell differentiation and undifferentiated
spindle-shaped sarcoma component possibly progressing from the
conventional tubular adenocarcinoma; an immunohistochemical and
ultrastructural study. Virchows Arch. 442:77–81. 2003.PubMed/NCBI
|
|
29
|
Lim SU, Seo SS, Yoon JY, Cho DH, Bae SY,
Bae WK, Shim HJ, Cho SH and Chung IJ: A case of gastric
adenocarcinoma developed in neuroendocrine carcinoma after
chemotherapy. Chonnam Med J. 44:188–193. 2008. View Article : Google Scholar
|
|
30
|
La Rosa S, Marando A, Sessa F and Capella
C: Mixed adenoneuroendocrine carcinomas (MANECs) of the
gastrointestinal tract: An update. Cancers (Basel). 4:11–30. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sato Y, Hashimoto S, Mizuno K, Takeuchi M
and Terai S: Management of gastric and duodenal neuroendocrine
tumors. World J Gastroenterol. 22:6817–6828. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Fukuda T, Ohnishi Y, Nishimaki T, Ohtani H
and Tachikawa S: Early gastric cancer of the small cell type. Am J
Gastroenterol. 83:1176–1179. 1988.PubMed/NCBI
|
|
33
|
Mitry E, Baudin E, Ducreux M, Sabourin JC,
Rufié P, Aparicio T, Aparicio T, Lasser P, Elias D, Duvillard P, et
al: Treatment of poorly differentiated neuroendocrine tumours with
etoposide and cisplatin. Br J Cancer. 81:1351–1355. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Okita NT, Kato K, Takahari D, Hirashima Y,
Nakajima TE, Matsubara J, Hamaguchi T, Yamada Y, Shimada Y,
Taniguchi H and Shirao K: Neuroendocrine tumors of the stomach:
Chemotherapy with cisplatin plus irinotecan is effective for
gastric poorly-differentiated neuroendocrine carcinoma. Gastric
Cancer. 14:161–165. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ip YT, Pong WM, Kao SS and Chan JK:
Spontaneous complete regression of gastric large-cell
neuroendocrine carcinoma: Mediated by cytomegalovirus-induced
cross-autoimmunity? Int J Surg Pathol. 19:355–358. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhang L, Qiu M, Jin Y, Ji J, Li B, Wang X,
Yan S, Xu R and Yang D: Programmed cell death ligand 1 (PD-L1)
expression on gastric cancer and its relationship with
clinicopathologic factors. Int J Clin Exp Pathol. 8:11084–11091.
2015.PubMed/NCBI
|
|
37
|
Gibney GT, Weiner LM and Atkins MB:
Predictive biomarkers for checkpoint inhibitor-based immunotherapy.
Lancet Oncol. 17:e542–e551. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Muro K, Chung HC, Shankaran V, Geva R,
Catenacci D, Gupta S, Eder JP, Golan T, Le DT, Burtness B, et al:
Pembrolizumab for patients with PD-L1-positive advanced gastric
cancer (KEYNOTE-012): A multicentre, open-label, phase 1b trial.
Lancet Oncol. 17:717–726. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kang YK, Boku N, Satoh T, Ryu MH, Chao Y,
Kato K, Chung HC, Chen JS, Muro K, Kang WK, et al: Nivolumab in
patients with advanced gastric or gastro-oesophageal junction
cancer refractory to, or intolerant of, at least two previous
chemotherapy regimens (ONO-4538-12, ATTRACTION-2): A randomised,
double-blind, placebo-controlled, phase 3 trial. Lancet.
390:2461–2471. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Park YH, Lee JL, Ryoo BY, Ryu MH, Yang SH,
Kim BS, Shin DB, Chang HM, Kim TW, Yuh YJ and Kang YK: Capecitabine
in combination with Oxaliplatin (XELOX) as a first-line therapy for
advanced gastric cancer. Cancer Chemother Pharmacol. 61:623–629.
2008. View Article : Google Scholar : PubMed/NCBI
|
